(Reuters) – Shares of obesity drug developer Altimmune fell 10% to $9.36 on Tuesday, after Kerrisdale Capital took a short position on the company’s stock.
Altimmune did not immediately respond to a request for comment.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Krishna Chandra Eluri)
Comments